Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06937931 · ClinicalTrials.gov registry record · Phase 2

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

A Phase 2 study of Cervical Dystonia, sponsored by Ipsen.

Recruiting
Registry status
Phase 2
Development phase
132
Enrollment target
20
Study locations

NCT06937931: Recruiting Phase 2 study of Cervical Dystonia, sponsored by Ipsen.

NCT06937931 is a Phase 2 study of Cervical Dystonia that is actively recruiting participants, run by Ipsen. The registered enrollment target is 132 participants, above the 78-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06937931, a Phase 2 study of Cervical Dystonia, is actively recruiting participants, sponsored by Ipsen.

RECRUITING
Registry status
Phase 2
Development phase
132 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults. CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role. The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period. The study will consist of two periods: 1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit. 2. A Treatment Period of 36 weeks. On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded. There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study. The total study duration for a participant will be up to 40 weeks (approximately 9 months).

Primary Outcome

The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is a rating scale for Cervical Dystonia (CD) consisting of three subscales: severity, disability and pain scales. The total score is the sum of each of the subscales, with a range of 0 to 85, where higher scores are indicative of greater impairment.

Conditions Studied

Cervical Dystonia

Interventions

  • OTHER Placebo
  • BIOLOGICAL IPN10200

Study Locations (20)

Other

  • Fakultni nemocnice u sv. Anny v Brne - I. Neurologicka klinika - Brno
  • MINKSneuro s.r.o. - Brno
  • NEUROHK s.r.o. - Choceň
  • Fakultni nemocnice Olomouc - Neurologicka klinika - Olomouc
  • Vseobecna fakultni nemocnice v Praze - Neurologicka klinika - Prague
  • CHU Grenoble Alpes - Site Nord - Neurology - Grenoble
  • Timone University Hospital - Marseille
  • CHU Nimes - Hôpital Caremeau - Nîmes
  • Hopitaux Universitaire de Strasbourg - Hopital de Hautepierre - Neurologie - Strasbourg
  • Centre Hospitalier Universitaire (CHU) Purpan - Institut Des Sciences du Cerveau De Toulouse (Institute for Brain Sciences) - Toulouse
  • Curiositas ad sanum Studien- und Beratungs GmbH Haag i.OB - Neurologie - Haag in Oberbayern

Florida

  • Parkinson's Ds & Mvt Disorders Cntr - Boca Raton
  • USF Health Byrd Alzheimer's Institute - Tampa

Arizona

  • University of Arizona Health Sciences - Neurology - Tucson

California

  • Parkinson's & Mvmt Disorders Inst - Fountain Valley

Georgia

  • Emory Brain Health Center - Atlanta

Illinois

  • Rush Medical Center - Chicago

Michigan

  • Quest Research Institute - Farmington Hills

New York

  • Ichan Sch of Medicine @ Mt. Sinai - New York

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2025-06-30
Est. Completion 2027-11-05
Phase Phase 2
Ipsen

85 total trials

What NCT06937931 shows while recruiting

NCT06937931 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (69% higher).

The record links to 1 condition, with Cervical Dystonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06937931 names 20 study sites across 9 states, led by Other, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06937931 about?

NCT06937931 is a clinical study titled "A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults". The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults. CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain ...

What is the current status of trial NCT06937931?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2025-06-30. Estimated completion is 2027-11-05.

What conditions does trial NCT06937931 study?

This clinical trial studies the following conditions: Cervical Dystonia.

What interventions are being tested in trial NCT06937931?

The interventions under investigation include: Placebo (OTHER), IPN10200 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06937931?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06937931 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Dystonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06937931's enrollment target sits among peer trials

132 4th of 15 higher than 12 of 15 other Cervical Dystonia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Dystonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06937931

Source: ClinicalTrials.gov NCT06937931, the US trial registry maintained by the National Library of Medicine. NCT06937931 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.